Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction

Leukemia

Volumn 23, Issue 7, 2009, Pages 1352-1355

  Mous, R ^a   Jaspers, A ^a   Luijks, D M P ^a   Mellink, C H M ^a   van Oers, M H J ^a   Kater, A P ^a   Eldering, E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; PROTEIN BAX; PROTEIN P21; PROTEIN P53; PUMA PROTEIN;

CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; LETTER; LEUKEMIA CELL; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 67650895047     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.71     Document Type: Letter

References (8)

1. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S et al Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799-804.
2. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814-822.
3. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443.
4. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, Bignell CR et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by m4jor differences in activating prosurvival responses. Blood 2004; 103: 291-300.
5. Carter A, Lin K, Sherrington PD, Pettitt AR. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425-428.
6. Malcikova J, Smardova J, Pekova S, Cejkova S, Kotaskova J, Tichy B et al. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia. Mol Immunol 2008; 45: 1525-1529.
7. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005; 19: 427-434.
8. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11 q deletion. J Clin Oncol 2007; 25: 5448-5457.